JPRN-jRCT2091220416已完成2 期
A phase 2 open label study to assess the efficacy and safety of beta-glucuronidase enzyme replacement therapy in Japanese patients with mucopolysaccharidosis type VII, Sly disease - beta-glucuronidase enzyme replacement therapy for Sly disease
Osaka City University HospitalTakashi Hamazaki0 个研究点目标入组 3 人开始时间: 2019年3月11日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
In this study, acceptable safety profile and the efficacy of Vestronidase-alpha treatment were confirmed in Japanese MPS VII patients at 24 weeks of administration.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 4age old 至 <= 40age old（—）
- 性别
- All
入选标准
- •1. Confirmed diagnosis of MPS 7 based on:
- •1) Reduced activity of leukocyte beta-glucuronidase
- •2) Clinical symptoms of Lysosomal disease (hepatomegaly,joint contracture,airway obstruction, pulmonary problems etc.)
- •2. Aged 4 to 40 years
- •3. Willing and able to provide written informed consent,or in the case of subjects under the age of 18, provide written assent (if required) and written informed consent by a legally authorized representative after the nature of the study has been explained,and prior to any research-related procedures
- •4. Sexually active subjects must have been willing to use acceptable highly effective methods of contraception while participating in the study and for 30 days following the last dose.
- •5. Females of childbearing potential must have had a negative pregnancy test at Screening and be willing to have had additional pregnancy tests during the study.
- •6. Naive to treatment with UX003
排除标准
- •1. Undergone a successful bone marrow or stem cell transplant or had any degree of detectable chimaerism with donor cells
- •2. Major surgery within 3 months prior to study entry or planned major surgery during the study that may not have allowed safe participation in the study
- •3. Presence or history of any hypersensitivity to rhGUS or its excipients that, in the judgment of the Investigator, placed the subject at increased risk for adverse effects
- •4. Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study
- •5. Use of any investigational product (drug or device or combination) within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments
- •6. Presence of a condition of such severity and acuity that, in the opinion of the Investigator, warranted immediate surgical intervention or other treatment or may not have allowed safe participation in the study
- •7. Concurrent disease or condition, or laboratory abnormality that, in the view of the Investigator, placed the subject at high risk of poor treatment compliance or of not completing the study, or would have interfered with study participation or introduced additional safety concerns
研究者
相似试验
已完成
2 期
Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast CancerProstate CancerNCT02130700Innocrin Pharmaceutical17
已完成
2 期
Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerOvarian CancerNCT00400348CASI Pharmaceuticals, Inc.18
终止
2 期
Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other CausalitiesPrimary Familial Dilated CardiomyopathyNCT04572893Bristol-Myers Squibb41
Unknown
2 期
A Study of Transgenic Lymphocyte Immunization (TLI) Against Telomerase in Subjects With Stage III MelanomaStage IIIB Skin MelanomaStage IIIC Skin MelanomaNCT00925314Cosmo Bioscience20
已完成
2 期
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate CancerCastration-resistant Prostate CancerCRPCNCT02012920Innocrin Pharmaceutical200